A Phase I, open-label, dose-escalation study of a B7-H6/CD3 antibody with or without ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6 (NCT04752215)
AUCT, area under the concentration–time curve over a uniform dosing interval; CD3, cluster of differentiation; Cmax, maximum measured concentration; CNS, central nervous system; CRC, colorectal cancer; DLT, dose-limiting toxicity; ECOG PS, Eastern Cooperative Oncology Group performance status; HCC, hepatocellular carcinoma; HNSCC, head and neck squamous cell carcinoma; MTD, maximum tolerated dose; NSCLC, non-small cell lung cancer; OR, objective response; PK, pharmacokinetic; Q1W, every week; Q3W, every 3 weeks; RECIST, Response Evaluation Criteria In Solid Tumors; TcE, T-cell engager.